Revenue

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue

Revenue

The following table provides information about disaggregated revenue by product line:

	Three Months Ended March 31,
(in thousands)	2022		2021
Assay services revenue	$	18,800	$	14,573
Product revenue	453		193
Collaboration revenue	763		763
Other revenue:
Royalties	2,955		3,000
Other	9		331
Total other revenue	2,964		3,331
Total revenue	$	22,980	$	18,860

Contract Balances and Remaining Performance Obligations

As of March 31, 2022 and December 31, 2021, deferred revenue of $34.6 million and $5.4 million, respectively, was comprised of balances related to our collaboration revenue, assay services, and other revenue. As of March 31, 2022 and December 31, 2021, the portion of deferred revenue related to collaboration revenue was $3.2 million and $3.9 million, respectively, which is being recognized on a straight-line basis over the period of performance. As of March 31, 2022, the estimated remaining performance period is 3.0 years. As of March 31, 2022 and December 31, 2021, the portion of deferred revenue related to assay services and other revenue was $1.4 million and $1.5 million, respectively. As of March 31, 2022, the deferred revenue related to assay services and other revenue will be recognized within 12 months.

As of March 31, 2022 and December 31, 2021 the deferred revenue related to the Illumina Agreement amounted to $30.0 million and nil, respectively. As of March 31, 2022, the estimated remaining performance obligation period is nine years.

A summary of the change in contract liabilities is as follows:

(in thousands)	March 31, 2022		December 31, 2021
Balance at beginning of period	$	5,385	$	5,177
Recognition of revenue included in balance at beginning of period	(1,132)		(1,762)
Revenue deferred during the period, net of revenue recognized	30,317		1,970
Balance at end of period	$	34,570	$	5,385